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Abstract
Background: Coeliac disease is a multifactorial inflammatory disorder of the intestine caused by
ingestion of gluten in genetically susceptible individuals. Genes within the HLA-DQ locus are
considered to contribute some 40% of the genetic influence on this disease. However, information
on other disease causing genes is sparse. Since enterocytes are considered to play a central role in
coeliac pathology, the aim of this study was to examine gene expression in a highly purified isolate
of these cells taken from patients with active disease. Epithelial cells were isolated from duodenal
biopsies taken from five coeliac patients with active disease and five non-coeliac control subjects.
Contaminating T cells were removed by magnetic sorting. The gene expression profile of the cells
was examined using microarray analysis. Validation of significantly altered genes was performed by
real-time RT-PCR and immunohistochemistry.
Results: Enterocyte suspensions of high purity (98–99%) were isolated from intestinal biopsies. Of
the 3,800 genes investigated, 102 genes were found to have significantly altered expression
between coeliac disease patients and controls (p < 0.05). Analysis of these altered genes revealed
a number of biological processes that are potentially modified in active coeliac disease. These
processes include events likely to contibute to coeliac pathology, such as altered cell proliferation,
differentiation, survival, structure and transport.
Conclusion: This study provides a profile of the molecular changes that occur in the intestinal
epithelium of coeliac patients with active disease. Novel candidate genes were revealed which
highlight the contribution of the epithelial cell to the pathogenesis of coeliac disease.
Background
Coeliac disease is a permanent intolerance to dietary
prolamins from wheat, barley and rye. Ingestion of these
proteins in susceptible individuals gives rise to an inflam-
matory lesion in the small intestine characterised by crypt
hyperplasia and villous atrophy [1]. While progress has
been made in understanding the mechanisms by which
prolamins activate the immune system, the molecular
events that ultimately lead to the intestinal lesion are, as
yet, ill defined.
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Coeliac disease has a strong HLA association with approx-
imately 95% of coeliac patients expressing the HLA-DQ2
molecule [2]. A large population-based study showed the
disease concordance rate between monozygotic twins to
be 75% [3]. This rate is considerably higher than that for
other multifactorial diseases such as Crohn's disease [4] or
insulin dependent diabetes mellitus [5]. However, in the
study by Greco et al, the concordance rate for coeliac dis-
ease in HLA-matched dizygotic twins was found to be
only 11% [3]. Thus, while the evidence points to a very
strong HLA genetic contribution to coeliac disease, other
non-HLA-linked genes must play a role.
Additional linkage studies have been performed in coeliac
disease in an attempt to identify susceptibility loci other
than the 6p21 HLA locus. Evidence has been found for
linkage with the non-HLA loci 2q33, 5q31-33 and 19p13
[6] and candidate gene association studies within these
loci have concentrated on genes known to be immunolog-
ically relevant to disease pathogenesis. Recent genome-
wide association studies have identified a region harbour-
ing IL-2 and IL-21 as a further potential genetic suscepti-
bility region predisposing to celiac disease [7,8]. However,
so far no gene has been conclusively proven to confer a
risk of coeliac disease. Hence, a hypothesis-free approach
to selecting genes for study, as employed here, may be use-
ful.
Much research in coeliac disease has focused on the role
of T-cells and the pro-inflammatory cytokines they pro-
duce [9-13]. It has been suggested that the direct effect of
pro-inflammatory cytokines such as IFN-γ and TNF-α may
contribute to the characteristic coeliac lesion [9]. Mem-
bers of the metalloproteinase (MMP) family have been
implicated in coeliac disease pathology. These enzymes
are capable of tissue remodelling by degradation of pro-
teins in the extracellular matrix and basement membrane.
Several studies have demonstrated elevated levels of MMP
expression in the coeliac lesion [14-16].
It has been proposed that dysregulated differentiation of
epithelial cells in the small intestine may also play a role
in the generation of the coeliac lesion. Diosdado et al have
suggested that stem cells in the villous crypt proliferate,
but do not receive the signal to differentiate leading to the
development of undifferentiated, hyperplastic crypts and
subsequently, villous atrophy [17]. It has recently been
reported that gliadin can directly cause up-regulation of
several epithelial cell surface molecules such as HLA-DR,
ICAM-1 and MICA [18]. Furthermore, other studies have
reported increased expression of several cytokines in the
epithelium of patients with active celiac disease including
IL-15, MIF, TNF-α and iNOS [19-21]. Thus, the intestinal
enterocyte is emerging as a potential contributor to coe-
liac disease pathogenesis and must be studied further.
The purpose of this study was to examine the role of the
epithelial cell in coeliac disease, employing a gene micro-
array based technique. This allowed for the analysis of the
simultaneous expression of thousands of gene transcripts,
in a hypothesis-free manner [22]. Epithelial cells were iso-
lated from biopsies taken from coeliac patients with active
disease and compared to controls, thereby examining the
gluten-induced inflammatory environment of the coeliac
lesion. In the study, 102 genes were found to have signif-
icantly altered expression. Further studies using RT-PCR
and immunohistochemistry were used to validate altered
expression of gap junction protein alpha 4 and small pro-
line rich protein 3.
Results
Microarray analysis of coeliac duodenal epithelial cells
DTT/EDTA treatment was employed to strip the epithelial
layer from patient intestinal biopsies. Magenetic cell sort-
ing was then used to deplete CD3+ cells, and enterocyte
suspensions with purities of 98–99% were routinely
obtained (Figure 1). Using Atlas Glass Human 3.8I oligo-
nucleotide micoarrays (BD Biosciences Clontech, UK), we
analysed the gene expression profile of a homogeneous
population of duodenal epithelial cells taken from
patients with active coeliac disease, in comparison to con-
trol patients. Of the 3,800 genes present on the array (all
of which have been previously annotated), 3549 had suf-
ficient data across the five experiments for comparison.
Many of these genes showed fold-change ratios with little
or no deviation from 1. Thus, to focus on only differen-
tially expressed genes, the list was filtered on a fold-
change of 1.25-fold. A fold-change of 1.25 has been
described in previously published microarray experiments
[23,24] and has been shown to indicate reliable differ-
ences in gene expression [23]. This filtering yielded a list
of 1,256 genes with which to perform analysis. Of these
1,256 genes, 827 were up-regulated and 429 were down-
regulated. A p-value of 0.05 was used as a cut-off to distin-
guish significantly expressed genes, which yielded a gene
list of 102 (68 up-regulated and 34 down-regulated) genes
which are presented in Table 1. These 102 genes were
grouped according to functional categories, including
protein transport, ion transport, proliferation, differentia-
tion, anti-apoptosis/survival, structural, adhesion, metab-
olism, transcription, protein biosynthesis, signal
transduction, cell cycle and DNA repair, and immune
response and inflammation (categories of genes and up/
down-regulation are summarised in Figure 2 and Table 2
respectively).
Verification of Selected Genes by Real-time PCR
In order to corroborate the microarray gene expression
results genes were selected for validation by real-time RT-
PCR using the same patient samples. Miron et al have
demonstrated that the popular strategy of selecting genesBMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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with the greatest fold-increase generally fails as a global
validation strategy while a random selection of genes for
validation (10–25 genes) is a more robust technique [25].
We therefore used random-stratified sampling as a gene
selection method. Ten genes representing a range of p-val-
ues were randomly selected for quantitative RT-PCR anal-
ysis.
The RT-PCR expression values were calculated from a
standard curve and the mean of the values calculated for
the coeliac samples was divided by the mean for the con-
trol samples to give a ratio. The RT-PCR ratios were then
compared to the microarray ratios (Table 3). Eight of the
ten genes showed up-regulation of expression in coeliac
disease with both microarray and real-time RT-PCR anal-
ysis. One gene showed up-regulation of expression in coe-
liac disease with microarray analysis and non-differential
expression with real-time RT-PCR. One gene showed
down-regulation of expression in coeliac disease with
microarray analysis and up-regulation of expression with
real-time RT-PCR analysis. Thus, 80% of the genes tested
in this study were found to be validated, which compares
well to a reported average RT-PCR confirmation rate of
70% [26].
Immunohistochemical Analysis
Two of the genes validated by real-time RT-PCR, were
selected for immunohistochemical examination based
upon their expression in the gastrointestinal tract and
potential interest with respect to coeliac disease patho-
physiology. Small proline-rich protein 3 (SPRR3) was
selected for qualitative analysis because of its role as a
structural protein and its potential to act as a substrate for
tissue transglutaminase [27]. Gap junction protein alpha
4 (GJA4) was selected because of recent literature suggest-
ing the importance of gap junctions in the spreading of
immune signals between epithelial cells, including small
peptides [28].
Protein expression of SPRR3 was examined in biopsies
from five further untreated coeliac patients and in corre-
sponding biopsies taken from these same patients at a
later date while consuming a gluten-free diet (Figure 3).
Histology reports showed that while consuming gluten,
all patients had Marsh 3 type lesions (one Marsh 3a, 2
Marsh 3b and 2 Marsh 3c). Upon adoption of a gluten-
free diet, two patients had recovered to normal duodenal
histology while three patients had recovered to type 3a
lesions with only mild or variable villous blunting. These
patients had been following a gluten-free diet for a mean
of 7 years (range 4–11 years).
In the untreated coeliac tissue the common finding was
intense cytoplasmic staining of SPRR3 throughout the
epithelial cell, with strongest staining observed on the api-
cal side of the cell. Perinuclear staining was also detected,
although less visible due to the intensity of the cytoplas-
mic staining. The staining was observed all along the epi-
thelium with the top part of the villous showing the
Flow cytometric analysis of purified epithelial cells Figure 1
Flow cytometric analysis of purified epithelial cells. 
A: Size versus granularity plot. B and C correspond to the 
population of cells within gate 1; and demonstrate control 
antibody and BerEP-4 expression, respectively. D and E cor-
respond to the population of cells within gate 2; and demon-
strate control antibody and CD3 expression, respectively.
102 differentially expressed genes organised by category Figure 2
102 differentially expressed genes organised by cate-
gory.B
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Table 1: Differentially expressed genes.
Functional Category Gene Name GenBank Accession Number Chromosome Location Fold-change p-value
Protein Transport peroxisome biogenesis factor 13 NM_002618 2p14-p16 2.276 0.00331
gap junction protein, alpha 4, 37 kDa (connexin 37) NM_002060 1p35.1 1.952 0.00575
syntaxin 3A NM_004177 11q12.1 1.81 0.00578
CD3G antigen, gamma polypeptide (TiT3 complex) NM_000073 11q23 1.547 0.00676
retinol dehydrogenase 5 
(11-cis and 9-cis)
NM_002905 12q13-q14 1.446 0.0158
exportin 1 
(CRM1 homolog, yeast)
NM_003400 2p15 1.847 0.0225
A kinase (PRKA) anchor protein 1 NM_005751 7q21-q22 0.748 0.0248
retinol binding protein 1, cellular NM_002899 3q21-q23 0.692 0.0305
Ion Transport gamma-aminobutyric acid (GABA) A receptor, beta 3 NM_000814 15q11.2-q12 1.74 0.00286
cholinergic receptor, nicotinic, alpha polypeptide 5 NM_000745 15q24 0.557 0.00605
hemochromatosis NM_000410 6p21.3 1.319 0.00924
potassium voltage-gated channel, Isk-related family, member 1 NM_000219 21q22.12 1.369 0.00959
calcium channel, voltage-dependent, L type, alpha 1C subunit NM_000719 12p13.3 1.351 0.0112
sorcin NM_003130 7q21.1 1.316 0.0248
ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A NM_001691 3q13.2-q13.31 1.47 0.0364
glutamate receptor, ionotropic, N-methyl D-aspartate 1 NM_000832 9q34.3 0.706 0.0368
adenosine kinase NM_001123 10q22.2 0.749 0.0406
Proliferation bone marrow stromal cell antigen 2 NM_004335 19p13.2 1.29 0.00975
PRKC, apoptosis, WT1, regulator NM_002583 12q21 0.73 0.0251
v-Ha-ras Harvey rat sarcoma viral oncogene homolog NM_005343 11p15.5 0.631 0.0282
growth arrest-specific 6 NM_000820 13q34 1.576 0.0443
Differentiation nuclear transcription factor Y, alpha NM_002505 6p21.3 0.714 0.0196
homeo box A7 NM_006896 7p15-p14 1.701 0.0297
ash2 (absent, small, or homeotic)-like (Drosophila) NM_004674 8p11.2 0.749 0.0368
wingless-type MMTV integration site family, member 7A NM_004625 3p25 1.33 0.044
Anti-apoptosis/Survival PTK2B protein tyrosine kinase 2 beta NM_004103 8p21.1 0.719 0.00362
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 NM_001396 21q22.13 2.627 0.0304
tumor necrosis factor receptor superfamily, member 18 NM_004195 1p36.3 1.941 0.0334
Erythropoietin NM_000799 7q22 2.738 0.0492
Transcription SRY (sex determining region Y)-box 14 NM_006942 17p13 0.732 0.0142
hematopoietic cell-specific Lyn substrate 1 NM_005335 3q13 1.585 0.0164
histone deacetylase 2 NM_001527 6q21 1.574 0.0178
high-mobility group box 3 NM_002128 13q12 1.775 0.02
ELK4, ETS-domain protein 
(SRF accessory protein 1)
NM_001973 1q32 1.446 0.0216
homeo box A11 NM_005523 7p15-p14 1.325 0.0246B
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forkhead box G1B NM_005249 14q13 1.558 0.0248
notch homolog 3 (Drosophila) NM_000435 19p13.2-p13.1 1.271 0.0285
paired box gene 8 NM_003466 2q12-q14 1.419 0.0289
human T-cell leukemia virus enhancer factor NM_002158 2p22-p16 1.267 0.0311
methyl CpG binding protein 2 (Rett syndrome) NM_004992 Xq28 0.532 0.0326
T-box 6 NM_004608 16p11.2 0.73 0.037
TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68 kDa
NM_003487 17q11.1-q11.2 0.656 0.0432
neuronal PAS domain protein 2 NM_002518 2q11.2 1.288 0.0497
Metabolism fructose-1,6-bisphosphatase 1 NM_000507 9q22.3 1.535 0.000296
glucosidase, beta; acid 
(includes glucosylceramidase)
NM_000157 1q21 1.258 0.000369
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) NM_002130 5p14-p13 0.535 0.00679
lipoprotein, Lp(a) NM_005577 6q26 1.653 0.0174
dihydropyrimidinase NM_001385 8q22 0.638 0.0205
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23 kDa 
(NADH-coenzyme Q reductase)
NM_002496 11q13 0.78 0.0242
histatin 1 NM_002159 4q13 0.75 0.0256
N-acetylgalactosaminidase, alpha- NM_000262 22q13-qter; 22q11 0.783 0.0278
choline kinase NM_001277 11q13.2 1.507 0.0303
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 NM_004567 3p22-p21 0.648 0.032
sterol regulatory element binding transcription factor 1 NM_004176 17p11.2 4.529 0.0354
Structural cytoplasmic linker 2 NM_003388 7q11.23 1.309 0.00603
procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine 
hydroxylase) 2
NM_000935 3q23-q24 1.563 0.00657
spectrin, alpha, erythrocytic 1 (elliptocytosis 2) NM_003126 1q21 1.29 0.0108
cystatin A (stefin A) NM_005213 3q21 1.48 0.0114
integrin beta 4 binding protein NM_002212 20q12 2.356 0.0167
envoplakin NM_001988 17q25 0.69 0.0201
tubulin-specific chaperone a NM_004607 5q14.1 0.725 0.0239
microtubule-associated protein 1A NM_002373 15q13-qter 0.652 0.0395
small proline-rich protein 3 NM_005416 1q21-q22 2.095 0.0398
Adhesion vinculin NM_003373 10q22.2 1.752 0.00217
matrix Gla protein NM_000900 12p13.1-p12.3 0.659 0.00909
EGF-containing fibulin-like extracellular matrix protein 1 NM_004105 2p16 1.276 0.0273
oligodendrocyte myelin glycoprotein NM_002544 17q11.2 2.008 0.0386
growth factor receptor-bound protein 7matrix Gla protein NM_005310 17q12 1.564 0.0479
Protein Synthesis ribosomal protein L19 NM_000981 17q11.2-q12 1.744 0.00118
eukaryotic translation elongation factor 1 beta 2 NM_001959 2q33-q34 1.413 0.0051
ribosomal protein S29 NM_001032 14q 1.311 0.00579
pyrroline-5-carboxylate reductase 1 NM_006907 17q25.3 1.31 0.0059
aminolevulinate, delta-, synthase 1 NM_000688 3p21.1 1.453 0.0105
eukaryotic translation initiation factor 4E binding protein 3 NM_003732 5q31.3 1.466 0.0143
Table 1: Differentially expressed genes. (Continued)B
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tyrosinase 
(oculocutaneous albinism IA)
NM_000372 11q14-q21 1.272 0.0387
Immune Response & Inflammation MAP/microtubule affinity-regulating kinase 2 NM_004954 11q12-q13 0.717 0.00307
microseminoprotein, beta- NM_002443 10q11.2 1.592 0.0113
sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase) NM_003032 3q27-q28 1.547 0.0207
pyruvate kinase, muscle NM_002654 15q22 1.438 0.031
superkiller viralicidic activity 2-like (S. cerevisiae) NM_006929 6p21 1.639 0.0401
Signal Transduction natriuretic peptide receptor A/guanylate cyclase A 
(atrionatriuretic peptide receptor A)
NM_000906 1q21-q22 0.693 0.00936
membrane protein, palmitoylated 3 (MAGUK p55 subfamily) 
member 3)
NM_001932 17q21.31 1.259 0.0109
GPI anchored molecule like protein NM_007264 12q13.3 1.791 0.0116
glutamate receptor, metabotropic 7 NM_000844 3p26.1-p25.1 0.768 0.026
G protein-coupled receptor 7 NM_005285 8p22-q21.13 2.293 0.0265
Ras-like without CAAX 1 NM_006912 1q22 1.306 0.0356
retinal G protein coupled receptor NM_002921 10q23 0.744 0.0458
AND-1 protein NM_007086 14q22.3 1.659 0.0465
Cell cycle & DNA repair developmentally regulated GTP binding protein 1 NM_004147 22q12.2 1.56 0.00551
protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 
(parvulin)
NM_006223 Xq13 0.628 0.0086
flap structure-specific endonuclease 1 NM_004111 11q12 1.288 0.0167
BRCA1 associated protein-1 
(ubiquitin carboxy-terminal hydrolase)
NM_004656 3p21.31-p21.2 1.316 0.0185
amyloid beta (A4) precursor protein-binding, family B, member 1 
(Fe65)
NM_001164 11p15 2.218 0.0234
ubiquitin protein ligase E3A (human papilloma virus E6-
associated protein, Angelman syndrome)
NM_000462 15q11-q13 0.771 0.0286
nudix (nucleoside diphosphate linked moiety X)-type motif 2 NM_001161 9p13 2.209 0.037
Miscellaneous chromosome 18 open reading frame 1 NM_004338 18p11.2 1.743 0.0298
prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-
Strausler-Scheinker syndrome, fatal familial insomnia)
NM_000311 20p13 0.539 0.00875
oxidase (cytochrome c) assembly 1-like NM_005015 14q11.2 0.625 0.0241
D-amino-acid oxidase NM_001917 12q24 1.75 0.03
chromosome X open reading frame 2 NM_001586 Xq28 0.762 0.0308
transmembrane 7 superfamily member 1 
(upregulated in kidney)
NM_003272 1q42-q43 0.761 0.0371
ribonuclease, RNase A family, 4 NM_002937 14q11.1 1.279 0.0467
Genes are ranked within each category according to their significance.
Table 1: Differentially expressed genes. (Continued)BMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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greatest intensity. Staining for SPRR3 was increased in the
untreated coeliac disease samples when compared to the
gluten-free diet samples in 4 out of 5 cases. In the fifth
matched sample, staining was equivalent pre and post-
treatment with the gluten-free diet. The treated coeliac tis-
sue generally showed faint staining in the villous-tip epi-
thelial cells, with occasional punctate staining of
moderate intensity also occurring only in the villous-tip
region. Biopsies from the five untreated coeliac patients
who showed up-regulation of SPRR3 mRNA expression by
microarray and RT-PCR analysis were also examined for
protein expression of SPRR3. All five samples showed a
similar intense staining picture as seen in the untreated
coeliac biopsies described above. Biopsies from ten nor-
mal control patients and ten disease control patients (con-
sisting of five with peptic duodenitis and five with Crohn's
disease with duodenal involvement) showed minimal
staining of the epithelium with only the villous-tip
involved, in a similar pattern to that found in the treated
coeliac tissue (data not shown).
Expression of GJA4 protein was compared between the
matched pairs of untreated and treated coeliac biopsies
(Figure 4). In the untreated epithelial tissue, granular
staining was predominantly seen in the cytoplasm of the
epithelial cells, with an increasing intensity towards the
brush border. Perinuclear staining was visible in some
cells although nuclear staining was generally absent. In
contrast, in the treated biopsies, nuclear staining of epi-
thelial cells was common while weak cytoplasmic staining
was only evident in the villous tips and brush border
staining was absent. The intra-epithelial lymphocytes
within the treated tissue showed the most intense nuclear
staining while the staining of enterocytes appeared to be
due to strong perinuclear staining. In biopsies from the
five untreated coeliac patients, who showed up-regulation
of GJA4 mRNA expression by microarray and RT-PCR
analysis, staining was similar to that seen in the untreated
coeliac biopsies described above. Biopsies from control
patients, both normal and diseased, showed a similar
staining pattern to that observed in treated coeliac tissue
although fewer cells appeared to stain positively in these
control tissues (data not shown). In particular, nuclear
staining was less frequent than in the treated coeliac tissue
while perinuclear staining remained a common finding.
Discussion
This is the first study to examine the gene expression pro-
file of a highly pure population of duodenal epithelial
cells in active coeliac disease. Differences in gene expres-
Table 2: Summary of microarray results by gene category.
Gene Category Genes Upregulated Genes Downregulated
Protein Transport 6 2
Ion Transport 6 3
Proliferation 2 2
Differentiation 2 2
Anti-apoptosis/Survival 3 1
Transcription 10 4
Metabolism 5 6
Structural 5 4
Adhesion 4 1
Protein Synthesis 7 0
Immune Response & Inflammation 4 1
Signal Transduction 5 3
Cell Cycle & DNA repair 5 2
Miscellaneous 3 4
Table 3: Comparison of fold-changes obtained for genes by microarray and by TaqMan RT-PCR
Gene RT-PCR fold-change Microarray fold-change
Peroxisome biogenesis factor 13 (PEX13) 1.62 2.28
Gap junction protein, alpha 4, (GJA4, aka connexin 37) 4.09 1.95
Syntaxin 3A (STX3A) 1.52 1.81
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (HMGCS1) 1.25 0.54
Sterol regulatory element binding transcription factor 1 (SREBF1) 1.26 4.53
Nudix (nucleoside diphosphate linked moiety X)-type motif 2 3.02 2.21
Small proline-rich protein 3 (SPRR3, aka Esophagin) 1.77 2.1
Sialic acid binding Ig-like lectin 6 (SIGLEC6) 3.14 1.89
Laminin 5, alpha 3 (LAMA3) 1.94 2.51
Low density lipoprotein receptor-related protein 6 (LRP6) 1.04 2.12BMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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sion between epithelial cells of coeliac patients on a nor-
mal, gluten containing diet and non-coeliac control
patients also consuming gluten were measured. Many of
the genes identified in the study are known to be
expressed in intestinal epithelial cells, [29-35] adding
validity to the results profile described here. Of the 3,800
genes present on the array, 102 genes were found to have
significantly altered expression in active coeliac disease.
Of these, ten genes were selected for validation by real-
time RT-PCR quantification and eight of the 10 showed
up-regulation in both detection systems. Protein expres-
sion of the gene product was investigated in the case of
two up-regulated genes and was increased in both.
The genes which demonstrated altered expression
included those involved in cell proliferation, cell differen-
tiation and cell death, all events which play a key role in
coeliac pathology. In the villous crypt compartment, stem
cells continuously proliferate to provide sufficient cells for
the epithelium to renew every five days [36]. Survival of
these crypt cells is key for the epithelium to maintain its
self-renewing capacity. Crypt hyperplasia is a further
important feature of the coeliac intestinal lesion and is
said to be the first architectural change in the pathogenic
process [37]. In active coeliac disease, it has previously
been noted that epithelial crypt cells proliferate at an
increased rate [38,39]. In this study, genes for growth
arrest-specific 6 (GAS6) and bone marrow stromal cell
antigen 2 (BST2) were found to be up-regulated in active
coeliac disease, and both have previously been reported to
induce cell proliferation [40,41]. In addition, the PRKC
apoptosis WT1 regulator gene (PAWR), known to act as a
negative regulator of proliferation [42], was found to be
down-regulated. These results show that the transcrip-
tional regulation of proliferation is altered in active coe-
liac disease and the findings are in keeping with those of
Diosdado et al [17] who also reported altered expression
of genes which lead to increased cell proliferation.
Differentiation is a key process in the intestinal epithe-
lium, whereby immature crypt cells become specialised
into mature enterocytes when they migrate up to the vil-
lous compartment. Altered expression of several genes
Immunohistochemical detection of SPRR3 in duodenal tissue Figure 3
Immunohistochemical detection of SPRR3 in duode-
nal tissue. A: treated coeliac, showing faint staining in vil-
lous-tip epithelial cells, with occasional punctate staining of 
moderate intensity; B: untreated coeliac (same patient as A) 
showing intense cytoplasmic staining throughout epithelial 
cells with strongest staining observed on apical side of cell; 
and C: normal control showing minimal staining of epithelium 
with only villous-tip involved.
Immunohistochemical detection of GJA4 in duodenal tissue Figure 4
Immunohistochemical detection of GJA4 in duodenal 
tissue. A: treated coeliac, nuclear staining of epithelial cells 
apparent while brush border staining absent; B: untreated 
coeliac (same patient as A), granular staining predominantly 
seen in cytoplasm of epithelial cells with increasing intensity 
towards brush border. Perinuclear staining visible in some 
cells although nuclear staining generally absent. C: normal 
control, showing perinuclear staining in the epithelium, simi-
lar to treated coeliac tissue, but with less frequent nuclear 
staining.BMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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which could affect this process was found in this study.
Wnt7a was found to be up-regulated and this signalling
pathway is known to have an important role in differenti-
ation and embryogenesis [43,44]. The importance of the
Wnt pathway in intestinal epithelium has been demon-
strated in animal studies. In a study by Kuhnert (2004) the
antagonism of Wnt signalling resulted in a marked
decrease in intestinal epithelial proliferation and a degen-
eration of intestinal architechture [45]. While up-regula-
tion of Wnt7A expression may provide a differentiation
signal to epithelial cells, signalling via Wnt7a has also
been shown to induce transcription of matrix metallpro-
teinase 12 (MMP-12) [17], an enzyme that has been
implicated in coeliac disease pathophysiology [46].
Altered expression of other genes points to a down-regu-
lation of epithelial differentiation. For example, nuclear
transcription factor Y alpha, a protein that has been
shown to induce the expression of differentiation markers
on CaCo-2 cells [47], was found to be down-regulated in
active coeliac disease. Expression of retinol binding pro-
tein 1 (RBP1) was also found to be reduced in active coe-
liac disease epithelium. Retinoids play an important role
in fundamental physiological processes including differ-
entiation of epithelial tissues. RBP1 is a protein that binds
metabolites of vitamin A, which has been shown to play a
role in the differentiation of epithelial cells. Given that
altered retinol metabolism is thought to play a part in
oncogenesis and RBP1 expression is lost in epithelial cells
of ovarian cancer (Cvetkovic 2003) lower levels of RBP1
may be associated with the increased chance of malig-
nancy in coeliac disease. Overall, these results provide evi-
dence for decreased differentiation of epithelial cells in
coeliac disease.
Several of the genes found to have altered expression in
this study would favour a decrease in apoptotic events.
These include the up-regulation of TNFRSF18 (also
known as glucocorticoid-induced TNFR-related gene) and
the survival factor erythropoietin which has been shown
to be involved in survival of human breast and cervix car-
cinoma cells [48]. Moreover, protein tyrosine kinase 2
beta (PTK2B), which enhances apoptosis [49] was found
to be down-regulated in active coeliac disease. These find-
ings concur with an earlier microarray study which found
evidence of activation of the NFκB pathway [17] which
can enhance cell survival by counteracting cell-death path-
ways [50]. Since crypt epithelial cells are in a hyper-prolif-
erative state in coeliac disease, enhancement of cell
survival by blocking apoptosis makes biological sense.
Although an increase in enterocyte apoptosis has been
reported in coeliac disease [18,51,52], this is not pro-
nounced and in one study only 2.4% of cells were apop-
totic [51]. Nonetheless, a certain level of apoptosis is to be
expected, as terminally differentiated cells are extruded
into the intestinal lumen from the villous tip. BRCA1
associated protein 1 (BAP1) was shown to have a signifi-
cantly elevated expression level in this study (1.316 fold-
change, p = 0.0185). This replicates a result generated by
Juuti-Uusitalo et al (2007) [53]. The significance of this
result is unclear but BAP1 has been described as a candi-
date tumour suppressor gene.
A number of genes involved in transport and metabolism
were also found to be differentially expressed. As the epi-
thelial layer in active coeliac disease is in disarray, the nor-
mal function of these cells is likely to become disordered.
Such changes in metabolism may reflect the modified
needs of rapidly renewing cells. Ion transport is known to
be increased in coeliac disease [54] and an up-regulation
of genes involved in ion channels was found in this study.
Examples of these include genes for the potassium volt-
age-gated channel, Isk-related family, member 1 (KCNE1)
and calcium channel, voltage-dependent, L type, alpha 1C
subunit (CACNA1C). A further gene involved in regulat-
ing iron transport, HFE, which is located on chromosome
6p21 (CELIAC locus 1) was also found to be up-regulated.
Interestingly, over-expression of HFE can lead to reduced
iron uptake [55], another known feature of coeliac dis-
ease. Juuti-Uusitalo et al. [24] also reported up-regulation
of genes affecting transport in coeliac patients and in par-
ticular the transcription of several ion pumps were upreg-
ulated.
Recent publications have suggested that activation of the
innate immune system in the epithelium of the small
intestine is a feature of coeliac disease. In this study we
identified 5 genes with altered expression that are
involved in the immune response. Mouse studies suggest
that one of the genes, MAP/microtubule affinity-regulat-
ing kinase 2 (MARK2), plays a role in maintenance of
immune system homeostasis and prevention of autoim-
munity [56]. The decreased expression of MARK2 may be
associated with the generation of autoimmunity in coeliac
disease. Another gene product, sialyltransferase 1 (beta-
galactoside alpha-2,6-sialyltransferase), appears to be
involved in the sialylation of O-glycans during the process
of dendritic cell maturation [57]. Increased expression of
this protein may reflect the maturation of antigen present-
ing cells in the inflammatory lesion.
In recent studies of coeliac disease, genes involved in the
intestinal barrier have been examined. One study reported
an increased association with the gene for myosin 9B
(MyO9B), involved in actin remodelling of epithelial cells
[58]. A number of other studies, however, have not con-
firmed this association [59,60]. In this study, no signifi-
cant alteration of expression of MyO9B was found and a
fold-change of just 1.1 was noted. Some other genes,
potentially involved in tight junction formation, did showBMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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an altered expression profile, although this did not reach
statistical significance; these were myosin 7A (1.5 up-
fold), claudin-5 (1.23 down-fold), cadherin-10 (1.39
down-fold) and actintin, alpha 1 (1.79 down-fold).
Small proline-rich protein 3 (SPRR3) was found to have
increased gene and protein expression in this study.
Intense cytoplasmic staining of this protein was noted in
the epithelial cells of untreated coeliac patients. SPRR3,
also known as esophagin, is a structural protein and a
member of the cornified cell envelope precursor family.
The cornified cell envelope provides a vital physical bar-
rier in certain specialised epithelia normally subjected to
mechanical trauma. The envelope is assembled by trans-
glutaminase cross-linking of several proteins including
SPRR3, which has been shown to be a substrate for trans-
glutaminase 1, 2 and 3 [27]. Expression of SPRR3 is nor-
mally found in terminally differentiated epithelia such as
the oesophagus but is up-regulated in response to epithe-
lial injury or disease [27]. The up-regulation of SPRR3 in
active coeliac disease may be a defensive response to pro-
tect the mucosa from any further damage caused by the
ingestion of gluten. The increased expression of trans-
glutaminase 2 found in the enterocytes and basement
membrane in active coeliac disease [61-63] could cross-
link with SPRR3 to form a cornified envelope-like barrier.
While SPRR3 is clearly upregulated in enterocytes in the
coeliac gut, it is not clear whether this response is gluten-
specific or the result of the architechtural changes typical
of coeliac disease. However, it is clear that SPRR3 protein
is not expressed to the same degree in disease control sam-
ples.
Gap junction protein, alpha 4 (GJA4) was also shown to
have increased gene expression and altered protein expres-
sion in patients with active coeliac disease. Granular GJA4
protein staining was found in these patients with an
increase towards the brush border. GJA4, also known as
connexin 37, is a member of the connexin family of gap
junction structural proteins. Gap junctional intercellular
communication can play various roles in terms of cell pro-
liferation, migration and differentiation [64] and in
atherosclerosis studies, connexin 37 expression has been
shown to change location as the disease progresses [65].
The potential influence of gap junctions on the immune
system is frequently overlooked. These channels can facil-
itate the transfer of small molecules like ions, metabolites
and peptides up to around 16 amino acids in length [28].
Gap junctions may function as a method to spread immu-
nological signals from, for example, viral infections from
cell to cell towards an antigen presenting cell such as an
interdigitating dendritic cell. The up-regulation of gap
junction proteins may reflect a response to the local
inflammatory mileu. Increased numbers of gap junctions
could facilitate the passage of immunostimulatory gluten
peptides between cells along the epithelial boundary.
Conclusion
This study investigated gene expression in highly purified
enterocytes from the duodenal biopsies of patients with
untreated coeliac disease and compared the findings with
age and sex-matched control subjects. By focusing on a
single cell population, in contrast to analysis of whole
biopsy tissue it was possible to exclude the contribution of
genes expressed in a diverse range of other cell types
within the coeliac lesion. Of the 102 genes found to have
significantly altered expression, several code for patholog-
ical processes known to contribute to coeliac disease and
other genes were identified which have not previously
been associated with this disorder. Of the ten genes inves-
tigated by real-time RT-PCR, validation of altered gene
expression was confirmed in 80% and in the case of two
proteins, increased duodenal expression was confirmed
by immunohistochemistry. The study demonstrates how
the application of microarray technology to the investiga-
tion of a complex genetic disease such as coeliac disease
can contribute to the elucidation of potential disease
mechanisms.
Methods
Patients
Duodenal biopsy specimens were obtained from each
patient via oesophago-gastro-duodenoscopy. Five coeliac
patients had active, untreated disease and five age and sex-
matched patients undergoing endoscopy for investigation
of upper gastrointestinal symptoms were used as a control
group. The demographic and clinical details of these
patients are given in Table 4. Eight biopsy samples from
each patient were used in microarray and RT-PCR experi-
ments and a further two biopsies were processed for rou-
tine histological evaluation.
In the immuno-histochemical studies, duodenal biopsy
samples from three further groups of patients were
employed. Archived tissue blocks in St. James's Hospital,
Dublin were the source of these samples. The study sub-
jects included five additional coeliac patients (3 males, 2
females, mean age 60 years): samples taken before they
had commenced a gluten free diet and after dietary treat-
ment (mean 7 years) were investigated. Two disease con-
trol patient groups were also studied: these included five
patients (2 female, 3 male, mean age 51 years) with
Crohn's disease involving the duodenum; and five
patients (2 female, 3 male, mean age 43 years) with peptic
duodenitis. Finally, a further ten patients (6 female, 4
male, mean age 59 years) undergoing endoscopy for
investigation of upper gastrointestinal symptoms were
also studied: this entire latter group had normal duodenal
histology.BMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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Ethical approval for this study was granted by the Joint
Ethics Committee of St James's Hospital and Tallaght
Hospital, Dublin, Ireland.
Isolation of epithelial cells
Enterocyte isolation was perfomed based upon previously
published methods [20]. The eight biopsies taken from
each patient were transferred into RPMI culture medium
containing 10% fetal calf serum and processed immedi-
ately. Biopsies were agitated in calcium and magnesium
free HBSS (Gibco BRL, Scotland) containing 1 mM dithi-
othreitol (DTT) (Sigma, USA) and 1 mM EDTA (Sigma,
USA) and incubated at 37°C for 40 minutes. The superna-
tant containing the epithelial cells was removed, washed
twice and centrifuged at 800 rpm for 10 minutes. Cells
were magnetically sorted to deplete CD3+ T-cells, using
MACS CD3 microbeads (Miltenyi Biotech, Germany) and
an LD depletion column according to manufacturer's
specifications (Miltenyi Biotech, Germany). Employing
the anti-epithelial cell monoclonal antibody Ber-EP4 and
the anti-T-cell monoclonal antibody CD3 (DAKO, Den-
mark), FACS analysis was performed on the eluted frac-
tion in order to determine purity and values of 98–99%
were repeatedly observed.
RNA extraction
Total RNA was extracted from the epithelial cells using the
NucleoSpin® RNA II kit (BD Biosciences Clontech, UK)
according to manufacturer's instructions with the follow-
ing exceptions: vigorous vortexing of cells in the lysis
buffer was performed, after which samples were frozen
and then thawed before continuing with extraction; RNA
was eluted from the column in 40 μl RNase-free water and
the eluate reloaded onto the column twice more in order
to collect the maximum yield of RNA. The RNA was con-
centrated further using Microcon YM-30 concentrators
(Millipore, Ireland). Total RNA was quantified at 260 nm,
and the 260/280 nm ratio was measured to calculate
purity of RNA from contaminating protein. Agarose gel
electrophoresis was also carried out to assess the quality of
RNA. The same RNA samples were used for both microar-
ray and RT-PCR analysis.
Synthesis of fluorescent-labelled cDNA probes
Fluorescent-labelled cDNA probes were synthesised using
the BD Atlas™ SMART™ Fluorescent Probe Amplification
Kit (BD Biosciences Clontech, UK). Briefly, cDNA was
reverse-transcribed from total RNA and purified from
unincorporated nucleotides before amplification using
the CyScribe GFX Purification Kit (Amersham Bio-
sciences, UK). From each patient specimen, two probe
samples were synthesised. For each sample, the optimum
number of PCR cycles was determined in order to ensure
the amplification process was stopped while still in the
exponential phase. This was essential as over-cycled cDNA
which has reached the plateau phase of amplification
could result in a less representative probe when examin-
ing differential gene expression. Once complete, an aliq-
uot of each sample was analysed on a 1.2% agarose/EtBr
gel under UV light, to ensure the reactions were successful.
The PCR product was purified using the CyScribe GFX
Purification Kit. Absorbance was read at 260 nm to calcu-
late quantity and the 260:280 nm ratio was measured to
calculate purity. Purified PCR product was fluorescently
labelled, according to manufacturer's instructions. Single-
use aliquots of monoreactive Cy3-NHS ester and Cy5-
NHS ester dyes (Amersham Biosciences, UK) dissolved in
DMSO were used. The labelled probe was purified from
unreacted dye using the CyScribe GFX Purification kit and
further purified from particulate matter by filtering
through a 0.22 μm spin filter. Quantity and quality of the
labelled probe was determined by UV/visible spectropho-
Table 4: Microarray Experiment Patient Clinical Details
Patients Sex Age Duodenal histology Other histology, clinical information Antibody status Microarray number
Coeliac
1 Female 61 Grade 3a none tTG + 1
2 Female 45 Grade 3b Barrett's oesophagus tTG + 2
3F e m a l e 2 2 G r a d e  1 n o n e t T G  + 3
4 Female 31 Grade 3c none tTG + 4
5 Female 36 Grade 3c mild reflux oesophagitis tTG + 5
Control
6 Female 58 NDM mild reflux oesophagitis nk 1
7 Female 51 NDM moderate reflux oesophagitis tTG - 2
8 Female 25 NDM none nk 3
9 Female 30 NDM superficial acute and chronic gastric inflammation nk 4
10 Female 26 NDM mild reflux oesophagitis tTG - 5
Histology grade: 0 = normal; 1 = raised intraepithelial lymphocytes (IELs); 2 = increase in IELs with crypt hyperplasia; 3a = increase in IELs, crypt 
hyperplasia, mild villous atrophy; 3b = increase in IELs, crypt hyperplasia, marked villous atrophy; 3c = total villous atrophy [37]. NDM = normal 
duodenal mucosa. tTG, tissue transglutaminase antibody. nk, not known.BMC Genomics 2008, 9:377 http://www.biomedcentral.com/1471-2164/9/377
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tometry using a Genesys 5 spectrophotometer (Thermo
Electron Corporation, US). The optimal volume of
labelled probe to use in the hybridisation reaction was
determined on the basis of absolute optical units (OUλ),
using the following formula:
where OUλ for Cy3 and Cy5 is 0.01 (determined by BD
Biosciences Clontech) and Aλ is the measured absorbance
maxima for each dye; 550 nm for Cy3 and 650 nm for
Cy5.
Microarray hybridisation and scanning
The microarrays used in this study were Atlas Glass
Human 3.8 I microarrays (BD Biosciences Clontech, UK).
Five biological replicate experiments were conducted,
each one comparing one untreated coeliac sample to one
control sample. In each experiment, two technical repli-
cates were performed. Onto one microarray, Cy3-labelled
coeliac cDNA and Cy5-labelled control cDNA were co-
hybridised. Onto the other microarray, Cy5-labelled coe-
liac cDNA and Cy3-labelled control cDNA were co-
hybridised. In this manner any discrepancies in rates of
incorporation of the different dyes during the labelling
step are controlled for. The appropriate coeliac and con-
trol probe were combined together and hybridised onto
the microarray according to manufacturer's specifications.
The slides were scanned using an Affymetrix®428™ Array
Scanner. Fluorescence was measured after excitation at
532 nm and 635 nm. Separate raw images for each dye
were acquired and images were analysed using the soft-
ware package ImaGene® 5.0 (BioDiscovery, California).
Quality control measures were performed on all spots to
identify empty, poor and negative spots.
Data analysis
The raw data from image analysis was normalised using
the free software ArrayNorm available at http://
genome.tugraz.at (Graz University of Technology Bioin-
formatics group, Austria). All the data was subjected to a
background subtraction followed by a Lowess normalisa-
tion performed separately on each block (subgrid) on
each microarray. Once normalised, the technical repli-
cates were averaged and the data saved as a text file. The
normalised data was analysed using the software package
GeneSpring® 7 (Silicon Genetics, California). A custom
genome was created using the genes present on the micro-
arrays used. The data was analysed using log of ratio and
the cross gene error model was turned off. The data was fil-
tered on confidence using the t-test with a p-value of 0.05
considered significant. Significantly differentially
expressed genes were grouped into functional categories
using MAPPFinder http://www.GenMapp.org – a program
that works with GenMAPP and the annotations from the
Gene Ontology (GO) Consortium [66].
Validation of data by real time RT-PCR
Genes to be validated were selected on the basis of signif-
icance and potential interest. The genes were chosen to
represent a spread of p-values up to 0.1. Assays-on-
Demand™ Gene Expression products (Applied Biosys-
tems, UK) containing forward primer, reverse primer and
probe labelled with FAM dye and MGB quencher in a sin-
gle tube were used. These primer/probe mixtures were pre-
designed by the manufacturer and pre-optimised to
ensure high amplification efficiency (proprietary
sequences).
Total RNA was reverse transcribed by standard methods.
cDNA samples were quantified using the Fluorescent
DNA Quantitation Kit (Bio-Rad, UK) according to manu-
facturer's specifications, and 250 pg of cDNA sample was
used per reaction. Fluorescence was measured on a Tecan
GENios Fluorimeter (Tecan, UK). Quantification of gene
expression was carried out in the ABI TaqMan 7000
(Applied Biosystems), using purified PCR products as
standards [67]. In order to compare the expression values
to those obtained from the microarray analysis, the mean
expression value of the five coeliac samples was divided
by the mean expression value of the five control samples
to give a single ratio value.
Immunohistochemistry
Immunohistochemical staining was performed on 3 μm
thick sections, cut from formalin-fixed, paraffin-embed-
ded biopsies, using the avidin-biotin-peroxidase complex
detection method. Rabbit polyclonal anti-human SPRR3
(small proline-rich protein 3) (Apotech UK), was applied
at a concentration of 1 in 1000 and rabbit polyclonal anti-
mouse connexin 37 (Alpha Diagnostic, US) was used at a
concentration of 1 in 150. The mouse connexin 37 immu-
nogenic peptide has an 87% homology to human con-
nexin 37. The selection of these two antibodies was based
on their known ability to react with human tissue [68,69].
The staining procedure was carried out using the
VECTASTAIN® Universal Elite ABC-Peroxidase Kit (Vector
Labs, USA), according to manufacturer's specifications.
Slides were visualised using a Nikon eclipse TE300 micro-
scope attached to a computer. Images were captured using
Leica DC100 and Adobe Photoshop software.
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